Review of Japanese Encephalitis Vaccines in India


  • Kripasindhu Chatterjee Department of Pediatrics, Santiniketan Medical College, Bolpur, West Bengal, India
  • Atanu Bhadra Department of Pediatrics, ESI Hospital, Asansol, West Bengal, India
  • Swapan Kumar Ray Department of Pediatrics, Mata Gujri Memorial Medical College and Lions Seva Kendra Hospital, Kishanganj, West Bengal, India
  • Subhasis Mukherjee Department of Physiology, Santiniketan Medical College, Bolpur, West Bengal, India
  • Sukanta Sen Department of Pharmacology, ICARE Institute of Medical Sciences and Research, Haldia, West Bengal India



Japanese Encephalitis, Vaccine, India


Japanese encephalitis virus belongs to the genus Flavivirus. Case fatality averages 30% and almost 50% of the survivors are left with permanent neuropsychiatric sequelae. Japanese encephalitis occurs in nearly all Asian countries including India. Patterns of JE transmission vary within individual countries and from year to year. In endemic areas, sporadic cases occur throughout the year. Japanese encephalitis or AES has been reported from 231 districts of 23 states. The best way to control JE in humans is through vaccination. Currently available vaccines in India are live attenuated, cell culture-derived SA 14-14-2, inactivated SA 14-14-2 vaccine (IC51; IXIARO® by Intercell and JEEV® by Biological Evans India Ltd.) and inactivated Vero cell culture-derived Kolar strain, 821564XY, JE vaccine (JENVAC® by Bharat Biotech). As 2006 position paper of WHO stated that mouse brain derived vaccines should be withdrawn and replaced by newer vaccines due to safety profile and as it is not available in our country now, this vaccine will not be discussed henceforth.


Download data is not yet available.




How to Cite

Kripasindhu Chatterjee, Atanu Bhadra, Swapan Kumar Ray, Subhasis Mukherjee, & Sukanta Sen. (2022). Review of Japanese Encephalitis Vaccines in India. Asian Pacific Journal of Health Sciences, 9(4), 272–283.

Most read articles by the same author(s)